Introduction

This page provides a comprehensive analysis of the known insider trading history of John P Sharp. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate John P Sharp has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PHAS / PhaseBio Pharmaceuticals Inc Chief Financial Officer 65,767
US:LGND / Ligand Pharmaceuticals Incorporated VP Finance and CFO 10,984
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by John P Sharp. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by John P Sharp as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-05-24 2022-05-20 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
A - Award 6,026 65,767 10.09 0.68 4,106 44,807
2022-02-28 2022-02-24 4 PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
A - Award 115,500 115,500
2022-02-28 2022-02-24 4 PHAS PhaseBio Pharmaceuticals Inc
Restricted Stock Unit
A - Award 24,750 24,750
2021-11-23 2021-11-19 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
A - Award 2,017 59,741 3.49 2.01 4,054 120,079
2021-11-03 2021-11-03 4 PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
M - Exercise -7,500 90,582 -7.65 1.68 -12,600 152,178
2021-11-03 2021-11-03 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
M - Exercise 7,500 57,724 14.93 1.68 12,600 96,976
2021-09-03 2021-08-03 4/A PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
M - Exercise -7,500 98,082 -7.10
2021-09-03 2021-08-03 4/A PHAS PhaseBio Pharmaceuticals Inc
Common Stock
M - Exercise 7,500 50,224 17.55 1.68 12,600 84,376
2021-08-04 2021-08-03 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
A - Award 7,500 50,224 17.55 1.68 12,600 84,376
2021-05-24 2021-05-20 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
A - Award 1,419 42,724 3.44 2.80 3,973 119,627
2021-02-09 2021-02-05 4 PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
A - Award 76,500 76,500
2020-11-23 2020-11-20 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
A - Award 1,305 41,305 3.26 3.00 3,915 123,915
2020-08-17 2020-08-14 4 PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
M - Exercise -5,000 105,582 -4.52
2020-08-17 2020-08-14 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
M - Exercise 5,000 40,000 14.29 1.69 8,450 67,600
2020-02-14 2020-02-12 4 PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
A - Award 100,000 100,000
2019-08-22 2019-08-21 4 PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
M - Exercise -5,000 4,038 -55.32
2019-08-22 2019-08-21 4 PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
M - Exercise -10,000 110,582 -8.29
2019-08-22 2019-08-21 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
M - Exercise 5,000 35,000 16.67 1.44 7,200 50,400
2019-08-22 2019-08-21 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
M - Exercise 10,000 30,000 50.00 1.69 16,900 50,700
2019-05-24 2019-05-22 4 PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
M - Exercise -15,000 120,582 -11.06
2019-05-24 2019-05-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
M - Exercise 15,000 20,000 300.00 1.69 25,350 33,800
2019-03-01 2019-02-27 4 PHAS PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy)
A - Award 100,000 100,000
2018-12-11 2018-12-07 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
P - Purchase 5,000 5,000 3.84 19,200 19,200
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -4,584 10,984 -29.45
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -1,166 0 -100.00
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -1,000 0 -100.00
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -14,622 8,582 -63.01
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -6,086 0 -100.00
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -7,495 347 -95.58
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy)
M - Exercise -8,333 0 -100.00
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy)
M - Exercise -6,012 0 -100.00
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy)
M - Exercise -7,321 6,012 -54.91
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy)
M - Exercise -16,666 0 -100.00
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy)
M - Exercise -2,879 8,917 -24.41
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy)
M - Exercise -10,789 13,125 -45.12
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -7,495 17,667 -29.79 74.27 -556,654 1,312,128
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 7,495 25,162 42.42 9.96 74,650 250,614
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -4,584 17,667 -20.60 74.27 -340,454 1,312,128
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 4,584 22,251 25.95 21.92 100,481 487,742
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -14,622 17,667 -45.28 74.27 -1,085,976 1,312,128
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 14,622 32,289 82.76 14.47 211,580 467,222
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -2,879 17,667 -14.01 75.73 -218,027 1,337,922
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 2,879 20,546 16.30 14.47 41,659 297,301
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -10,789 17,667 -37.91 75.73 -817,051 1,337,922
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 10,789 28,456 61.07 10.05 108,429 285,983
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -6,086 17,667 -25.62 74.27 -452,007 1,312,128
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 6,086 23,753 34.45 10.05 61,164 238,718
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -6,012 17,667 -25.39 75.73 -455,289 1,337,922
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 6,012 23,679 34.03 21.00 126,252 497,259
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -7,321 17,667 -29.30 74.27 -543,731 1,312,128
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 7,321 24,988 41.44 21.00 153,741 524,748
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -8,333 17,667 -32.05 75.73 -631,058 1,337,922
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 8,333 26,000 47.17 40.86 340,486 1,062,360
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -1,000 17,667 -5.36 74.27 -74,270 1,312,128
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 1,000 18,667 5.66 16.14 16,140 301,285
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -16,666 17,667 -48.54 74.27 -1,237,784 1,312,128
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 16,666 34,333 94.33 16.14 268,989 554,135
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -1,166 17,667 -6.19 74.27 -86,599 1,312,128
2014-02-14 2014-02-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 1,166 18,833 6.60 21.00 24,486 395,493
2013-12-16 2013-12-12 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -700 7,842 -8.19
2013-12-16 2013-12-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -700 17,667 -3.81 53.44 -37,408 944,124
2013-12-16 2013-12-12 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 700 18,367 3.96 9.96 6,972 182,935
2013-12-09 2013-12-06 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -6,000 17,667 -25.35 56.08 -336,480 990,765
2013-11-20 2013-11-18 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -624 8,542 -6.81
2013-11-20 2013-11-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -1,123 23,667 -4.53 53.00 -59,519 1,254,351
2013-11-20 2013-11-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 624 24,790 2.58 9.96 6,215 246,908
2013-08-20 2013-08-16 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -7,500 9,166 -45.00
2013-08-20 2013-08-16 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
S - Sale -7,500 24,166 -23.68 42.75 -320,619 1,033,077
2013-08-20 2013-08-16 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
M - Exercise 7,500 31,666 31.04 9.96 74,700 315,393
2013-02-19 2013-02-15 4 LGND LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
A - Award 15,568 15,568 21.92 341,251 341,251
2013-02-19 2013-02-15 4 LGND LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy)
A - Award 4,432 4,432 21.92 97,149 97,149
2013-02-19 2013-02-15 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock
A - Award 2,500 24,166 11.54
2012-02-13 2012-02-09 4 LGNDD LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
A - Award 23,204 23,204 14.47 335,762 335,762
2012-02-13 2012-02-09 4 LGNDD LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy)
A - Award 11,796 11,796 14.47 170,688 170,688
2012-02-13 2012-02-09 4 LGNDD LIGAND PHARMACEUTICALS INC
Common Stock
A - Award 5,000 21,666 30.00
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)